Ultragenyx Pharmaceutical Inc. (RARE)
US — Healthcare Sector
Automate Your Wheel Strategy on RARE
With Tiblio's Option Bot, you can configure your own wheel strategy including RARE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RARE
- Rev/Share 6.197
- Book/Share 1.6076
- PB 19.2123
- Debt/Equity 5.836
- CurrentRatio 2.4546
- ROIC -0.4662
- MktCap 2844889632.0
- FreeCF/Share -4.3398
- PFCF -6.6578
- PE -5.4539
- Debt/Assets 0.6759
- DivYield 0
- ROE -2.3748
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | RARE | H.C. Wainwright | -- | Buy | -- | $80 | July 28, 2025 |
| Initiation | RARE | William Blair | -- | Outperform | -- | -- | May 28, 2025 |
News
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
RARE
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
RARE
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
2024 Total Revenue of $560 million, exceeding guidance Crysvita® revenue of $410 million and Dojolvi® revenue of $88 million
Read More
About Ultragenyx Pharmaceutical Inc. (RARE)
- IPO Date 2014-01-31
- Website https://www.ultragenyx.com
- Industry Biotechnology
- CEO Emil D. Kakkis
- Employees 1294
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.